cancer, Pfizer
Pharmaceutical giant Pfizer ( PFE 0.38%) stands out in this context. The company currently offers a mouthwatering 5.7% ...
The drugmaker’s fastest-growing blockbuster could soon face competition from two biotech firms in the treatment of a ...
Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug ...
Cancer patients with wasting syndrome have gained weight after taking Pfizer’s anti-GDF-15 antibody in a midphase study, ...
One of the biopharma industry’s marvels of the 2020s has been the enormous medical and financial success of the GLP-1 class ...
Shares of Pfizer Inc. PFE inched 0.38% higher to $29.27 Friday, on what proved to be an all-around favorable trading session ...
Pfizer Inc. (PFE) said Saturday that its Phase 2 study of ponsegromab, a monoclonal antibody directed against growth differentiation ...
We came across a bullish thesis on Pfizer Inc. (PFE) on gurufocus by Akim Guerreiro. In this article we will summarize the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback